Kamada (KMDA): Kamada to supply investigational IgG pro...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	145
Posts	27554
Boards Moderated	3
Alias Born	02/07/2004

midastouch017

Re: None

Monday, 10/19/2020 9:25:09 AM

Monday, October 19, 2020 9:25:09 AM

Kamada to supply investigational IgG product for COVID-19

Oct. 19, 2020 9:21 AM ET|About: Kamada Ltd. (KMDA)|By: Meghavi Singh, SA News Editor

Kamada (NASDAQ:KMDA) +11% premarket, after signing an agreement with the Israeli Ministry of Health ((MoH)) to supply its anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin (IgG) investigational product as a potential treatment for COVID-19 patients in Israel.

The initial order of $3.4M in revenue is expected to be supplied during the beginning of 2021 to treat ~500 hospitalized patients.

Kamada will manufacture the product to be supplied to MOH from convalescent plasma collected and supplied by the Israeli National Blood Services, a division of Magen David Adom (MADA), and additional Israeli medical institutions.

In September 2020, announced interim data from Phase 1/2 IgG trial in COVID-19.

The companies’ US clinical development of a plasma-derived IgG product as a potential COVID-19 treatment is expected to begin in early 2021 pending IND acceptance.